Monday, December 20, 2021

bell hooks will never leave us – she lives on through the truth of her words

I was introduced to the work of bell hooks for the first time when I was 14 years old, sitting on my Nana’s porch, complaining about the mosquitoes and the heat.

My Nana, who was probably frustrated by my endless complaints about being bored, stuck a copy of “Ain’t I A Woman” in my hand and told me just to “shut up and read.” I remember that summer because after I read that book, all we talked about was bell hooks and who she was and who I wanted to be. I said then that I wanted to be a writer, like bell hooks, and change the world with my words.

Tuesday, December 7, 2021

Progressive Lawmakers to Biden: 'Cancel Student Loan Debt.' All of It. Now.


 

"Student loan payments resume in 61 days. Borrowers are NOT ready or able to restart them," said Democratic Congresswoman Pramila Jayapal.

ANDREA GERMANOS

December 3, 2021

A group of progressive lawmakers is urging the Biden administration to cancel student debt—a call they say is especially urgent in light of the fast-approaching end to a pandemic-related moratorium on payments.

"This is a crisis created through policy decisions."

"Student loan payments resume in 61 days. Borrowers are NOT ready or able to restart them," Rep. Pramila Jayapal (D-Wash.), chair of the Congressional Progressive Caucus, tweeted late Thursday.

"It's time for @POTUS to cancel student debt," she said.

Jayapal was among a number of progressive House Democrats who took to the floor Thursday to highlight the need for sweeping relief, some of whom spoke of their own lingering student debt burden.

Thirty-two-year-old Rep. Alexandria Ocasio-Cortez (D-N.Y.), who said the crisis—which now stands at over $1.8 trillion and affects roughly 45 million Americans—had reached a "ridiculous" level, noted that she still has over $17,000 in student loan debt and that the prospect of going deeper into debt prompted her decision not to pursue graduate school.

Part of the problem, she said, is that it can be "teenagers signing up for what is often hundreds of thousands of dollars of debt... and we think that's responsible policy."

"This is unacceptable," she said, adding federal policies in the U.S. are "actively disincentivizing" people from growing to college—a situation she called "backwards."

As Rep. Ayanna Pressley (D-Mass.) pointed out in her remarks, the educational debt isn't merely a problem for those recently out of school.

"I have 76-year-old constituents in the Massachusetts 7th still paying student loans," she said, "all while on Social Security and a fixed income."

President Joe Biden using his executive authority to wipe out $50,000 per borrower in student debt, said Pressley, would be "one of the most effective ways that he can provide sweeping relief to millions of families while helping to reduce the racial wealth gap to lay the groundwork for an equitable and just long term recovery."

"This is a crisis created through policy decisions," she added. "We have a responsibility to address it head-on."

Progressive groups and lawmakers have urged Biden to exercise the legal authority they say he has under Section 432(a) of the Higher Education Act to cancel student debt.

As of Thursday, the White House has not indicated a further extension of the loan payment pause relief, and while Education Department officials this week lamented the student debt crisis and touted the administration's efforts to provide relief to a small subsection of borrowers, a plan for broad debt cancellation was not put on the table.

In addition, a draft memo Biden requested on his authority over the cancelation was obtained through a Freedom of Information Act request by the Debt Collective—but it is nearly entirely redacted and has still not been made visible to the public.

The lawmakers' remarks came as new polling showed a dire economic situation by some borrowers as the payment moratorium ends at the end of January.

According to the survey by advocacy group Student Debt Crisis Center (SDCC) and technology company Savi from Nov. 1-Nov.14, 89% of fully-employed student loan borrowers said they are not financially secure enough to resume payments when they start back up in less than two months.

Nearly as many respondents (87%) said the temporary loan relief made it possible for them to afford other bills during the Covid-19 crisis.

The survey findings, said SDCC president and founder Natalia Abrams, show "that student loan borrowers face economic obstacles that are larger and longer-lasting than we imagined. As the economy recovers, even fully-employed student loan borrowers are not financially secure enough to make payments again."

"Simply put," she said, "Americans with student debt aren't facing an employment crisis, they are facing a student debt crisis."


This article originally appeared at CommonDreams.org. Originally published on December 3rd, 2021.It is licensed under a Creative Commons Attribution-Share Alike 3.0 License. 

Please support and visit The Brooks Blackboard's websiteour INTEL pageOPEN MIND page, and LIKE and FOLLOW our Facebook page.

Follow me on Twitter at @_CharlesBrooks   

Friday, December 3, 2021

Vaccine apartheid is prolonging COVID – not vaccine hesitancy

There’s a colonial tendency to portray people in Africa as anti-science and averse to progress, when the real problem is Big Pharma’s monopoly


By Alena Ivanova

Next week will mark the first anniversary of the NHS administering the first COVID-19 vaccine outside of clinical trials in a hospital in Coventry. Almost a year on from 8 December 2020, the Omicron variant threatens to ruin yet another holiday season and raises questions about the UK government’s approach.

But we already knew of the dangers of vaccine inequality. While the UK this morning announced it had ordered an additional 114 million COVID vaccine doses – despite around 85% of its adult population being fully vaccinated – just 6% of Africa’s 1.2 billion people have received two doses. And hastily reimposed travel bans on people from the African continent reveal more than the refusal of governments in the Global North to deal with the crisis at hand. The racist scapegoating of Black people has a history as old as public health itself.

There is no conclusive evidence that the new travel ban imposed by the UK on six countries in southern Africa will be effective. Indeed, there is plenty of evidence to show that the new variant was circulating in Europe much before Omicron was identified in South Africa, thanks to the scientific rigour and openness of South African researchers. Arbitrary travel bans can affect scientific cooperation and knowledge-sharing, as Tulio de Oliveira, director of South Africa’s Centre for Epidemic Response & Innovation, has warned. He tweeted that travel restrictions mean laboratories don’t get essential supplies.

But politicians and CEOs in the Global North have been busy excusing their dreadful track record on cooperation with low- and middle-income countries, blaming the low vaccination levels in southern Africa on hesitancy. Soundbites such as Pfizer CEO Albert Bourla’s claim that vaccine hesitancy in low-income countries is “way, way higher than the percentage of hesitancy in Europe or in the US or Japan”, have angered many, who have accused them of being tropes grounded in racism – akin to those used during the HIV crisis. In reality, research has suggested a higher willingness to take COVID vaccines in lower- and middle-income countries. But portraying people in Africa as anti-science and averse to progress has long been the coloniser’s excuse to dominate and subjugate and we should not be surprised that it keeps rearing its ugly head. What’s worrying is the speed with which such excuses are adopted by the UK government, while being left unchallenged by the media.

Britain’s Africa minister, Vicky Ford, has repeatedly evaded the issue of vaccine supplies to low- and middle-income countries, focussing instead on their vaccine hesitancy when questioned in Parliament. But research shows no basis for such claims. Africa’s problem is not hesitancy but the fact that many of its healthcare systems are ravaged by privatisation, often imposed by countries such as the UK. Is it any wonder that most African countries are unable to respond quickly and efficiently to the uncertain supply of donated vaccines that arrive with little warning?

Even the so-called ‘level-playing field’ of the market doesn’t seem to deliver for African countries. Earlier this year, Botswana ordered 500,000 doses of the Moderna vaccine at a higher price than was paid by some richer countries. Delivery was expected in August, but as Zain Rizvi, a drug policy expert at US think tank Public Citizen, has noted, none had appeared by October.

What’s more, vaccine hesitancy exists everywhere. The early stages of the vaccination programme in Europe were marred by controversy around the Oxford-AstraZeneca jab, with several countries suspending the inoculation drive or switching vaccines by age group. Even now, enclaves of vaccine hesitancy and mistrust remain across the continent, yet nobody seems to deny European countries the right to an adequate supply of doses.

So where do we really stand on vaccine inequality? COVAX, the global mechanism that was supposed to facilitate equal sharing of doses through a centralised donation and purchasing scheme, has failed. Its original goal of distributing two billion doses across the world during 2021 won’t be met. Instead, COVAX now has a revised goal of distributing 1.45 billion doses by the end of the year. But at the time of writing, only 589 million doses had been shipped; shockingly half a million of those were delivered to the UK.

Pharmaceutical companies tell us that supply is not the problem. Yet, with rich countries guzzling the existing doses and refusing to share equally, the only just solution is to expand supply. But a waiver on intellectual property rights for COVID-19 vaccines, treatments and tests – a proposal to increase production that is supported by much of the world –is being blocked by the same countries that have hoarded doses and protected the financial interests of big pharma.

This article originally appeared at opendemocracy.net on and originally published on December 2, 2021.  This article is published under a Creative Commons Attribution-NonCommercial 4.0 International licence. 

Please support and visit The Brooks Blackboard's websiteour INTEL pageOPEN MIND page, and LIKE and FOLLOW our Facebook page.

Follow me on Twitter at @_CharlesBrooks